Introduction {#Sec1}
============

Although twin studies first documented the high heritability of bipolar disorder (BD) decades ago, only recently have robustly associated genetic risk loci been identified through genomewide association studies (GWAS)^[@CR1]--[@CR8]^. At present, the major rate-limiting step for GWAS of BD is the need for ever-larger sample sizes to detect both common modest-effect variants and rarer large effect variants. In recent years, the widespread adoption of longitudinal electronic health records (EHRs) has provided a vast and growing repository of phenotypic data that can be leveraged for psychiatric research^[@CR9]^. In particular, when linked to sample collections through biobanks and other efforts, EHR data provide a relatively untapped opportunity to enhance the power of genetic research. Nevertheless, establishing the validity of EHR-derived phenotypes remains an important pre-requisite for leveraging these resources.

In an effort to rapidly increase available samples for genomewide studies of BD, we established the International Cohort Collection for Bipolar Disorder (ICCBD) through which we applied high-throughput phenotyping methods at sites in the United States (US), United Kingdom (UK), and Sweden^[@CR7]^. At the US site (Partners Healthcare), we developed and applied EHR phenotyping algorithms to identify approximately 4500 cases and 5000 controls for whom DNA was obtained from discarded blood samples. The use of EHR data to define valid phenotypes is particularly challenging for psychiatric disorders. Because there are no pathognomonic laboratory or pathologic findings, psychiatric diagnosis has traditionally relied on self-reported symptoms, behavioral observations, and clinical judgment. Thus, genomic studies have typically utilized structured or semi-structured diagnostic interviews as the gold-standard method to establish case and control status. EHR data, on the other hand, are limited to information (e.g., billing codes, medication lists, and narrative notes) collected in the course of clinical care rather than for research purposes. Recognizing this, we have undertaken systematic efforts to evaluate the validity of our EHR-based phenotyping algorithms.

In an earlier report^[@CR10]^, we described the development of our automated phenotyping algorithms for BD cases and controls. Briefly, we developed four case definitions, one of which included natural language processing of narrative EHR notes and three based on structured coded data using rule-based classifiers that differed in their stringency. Another rule-based algorithm was developed to identify controls. To establish the clinical validity of these algorithms, we conducted an in-person diagnostic validation study (*N* = 190) in which algorithm diagnoses were compared to diagnoses made by blinded expert clinicians using a gold-standard in-person diagnostic interview (SCID-IV). Three of the four case definitions achieved high positive predictive value (PPV) compared with diagnostic interviews (up to 0.86) and the PPV for the control algorithm was 1.0. Thus, we demonstrated that automated EHR-based phenotyping can be used to identify clinically valid case and control definitions for BD. However, an important remaining question is whether these case and control sets are genetically comparable to traditionally ascertained samples that have been used in most genomic studies of BD. This is an important issue in evaluating whether EHR-based samples can be combined (e.g., through meta-analyses) with data from other ongoing genomic studies (e.g., by consortia such as the Psychiatric Genomics Consortium) to enhance gene discovery.

Here, we report genetic validation of our EHR phenotyping algorithms by using genomewide data to estimate their SNP-based heritability (*h*^2^~g~) and genetic correlation (*r*~g~) with other large-scale traditionally ascertained BD GWAS samples. We further examined genetic correlations with other phenotypes of interest and performed genome-wide heterogeneity testing to validate the consistency of genome-wide association results. Our results demonstrate that automated EHR phenotyping can be used to assemble case/control cohorts that are both clinically and genetically comparable to traditionally ascertained samples and thus represent a valuable tool for accelerating psychiatric genetic research.

Materials and methods {#Sec2}
=====================

Study subjects {#Sec3}
--------------

Cases and controls were collected as part of the International Cohort Collection for Bipolar Disorder (ICCBD), a US, UK, and Swedish consortium established to accelerate genomic studies of BD by applying high throughput phenotyping methods^[@CR7],[@CR10]^. The Massachusetts General Hospital site of the ICCBD aimed to collect DNA from 4500 cases and 4500 controls by linking discarded blood samples to de-identified EHR data. As described in detail elsewhere^[@CR10]^, cases and controls were identified by deriving EHR-based phenotyping algorithms applied to the Partners Healthcare Research Patient Data Registry (RPDR), which spans more than 20 years of data from 4.6 million patients. As the first step in building our BD phenotyping algorithms, we created a "datamart" of 52,235 individuals by filtering medical records to identify patients seen at Massachusetts General Hospital, Brigham and Women's Hospital, or McLean Hospital who had at least one diagnosis of bipolar disorder (ICD- 9 and DSM-IV-TR codes 296.4\*--296.8\*) or manic disorder (ICD 296.0\*--296.1\*). Next, four phenotyping algorithms were developed to identify cases and one algorithm to identify controls.

The development and clinical validation of case and control algorithms described here is adapted from Castro et al. ^[@CR10]^. The five phenotyping algorithms developed comprised the following:95-NLP: This BD case algorithm incorporated natural language processing (NLP) of narrative notes using the i2b2 suite of software^[@CR11]^. Expert clinicians manually reviewed 612 notes from 209 randomly selected patients to identify gold-standard cases and to extract relevant features from narrative notes to be processed by NLP. We trained a model based on 414 features to predict the probability of BD using a logistic regression classifier with the adaptive least absolute shrinkage and selection operator (LASSO) procedure. The final model, comprising 13 features, achieved an area under the receiver operating curve (AUC) of 0.93, with a sensitivity of 0.53 when the specificity was set to 0.95.Coded-strict: This algorithm was a rule-based classifier that required at least three ICD codes for BD, a predominance of BD diagnoses in the longitudinal record, and either (a) treatment with lithium or valproate within a year of BD diagnosis or (b) treatment at a bipolar specialty clinic.Coded-broad: This algorithm required at least two ICD codes for BD, a predominance of BD diagnoses, and treatment with at least two bipolar medications (lithium, valproate, carbamazepine, or an atypical antipsychotic).Coded-broad-SV: This algorithm was the same as "Coded-broad" except that two or more BD diagnoses were allowed to occur during the same inpatient or outpatient episode of illness.Controls: This algorithm defined controls as those age 30 years or older with no ICD-9 codes or history of medications related to a psychiatric or neurological condition.

As reported earlier, we conducted a direct-interview study to examine the predictive validity of these algorithms. Patients in the Partners Healthcare system who were identified by each algorithm as BD cases or controls were invited by mail to participate. Participants in the validation study were independent of the patient samples on which the algorithms were trained. After informed consent was obtained, participants underwent semistructured diagnostic interviews (SCID-IV) conducted by experienced doctoral-level clinicians blinded to classifier diagnosis. To further preserve clinician blinding, we recruited individuals from MGH clinics who reported a previous diagnosis of schizophrenia or major depressive disorder, disorders commonly considered in the differential diagnosis of BD. The protocol was approved by the Partners HealthCare system institutional review board. A total of 190 participants were interviewed and PPVs for each algorithm were calculated as the proportion of algorithm defined BD cases (or controls) who received a concordant diagnosis by SCID interview. The PPVs for each algorithm using a non-hierarchical approach (where each case was assigned to any algorithm for which they satisfied inclusion criteria) are shown in Table [1](#Tab1){ref-type="table"} and reported in Castro et al.^[@CR10]^.Table 1SNP-based heritability (*h*^2^g) for EHR-based bipolar disorder from the Partners Healthcare Research Patient Data RegistryBipolar disorder algorithms*h*^2^~g~ (SE)Sample sizeLiability scaleObserved scale*P*-value^b^PPVcasescontrols95-NLP0.24 (0.10)0.25 (0.10)0.0150.868623952Coded-strict0.09 (0.05)0.15 (0.08)0.0640.8419683952Coded-broad0.13 (0.04)0.22 (0.08)0.0030.8025813952Coded-broad-SV0.00 (0.11)0.00 (0.18)0.5910.504083952All except coded-broad-SV0.12 (0.04)0.21 (0.07)0.0040.8330133952ICCBD + PGCBD^a^0.23 (0.01)0.41 (0.02)3.17 × 10^−80^NA1390219279SNP-based heritability on liability scale was converted from observed scale based on population prevalence of 1%^a^ICCBD + PGCBD: Bipolar disorder genome-wide association study from the ICCBD and PGC1 with cases ascertained by traditional methods (Charney et al.^[@CR7]^)^b^Test for *h*^2^~g~ different from 0. PPV: positive predictive values from clinical validation (Castro et al.^[@CR10]^). 95-NLP: probabilistic algorithm with 95% specificity based on natural language processing. Coded-strict, Coded-broad, Coded-broad-SV: coded rule-based algorithms with decreasing stringency. SV: single visit. SE: standard error

DNA sample collection and genotyping {#Sec4}
------------------------------------

The phenotyping algorithms were applied to the Partners Healthcare system to ascertain case and control DNA samples by linking phenotypic data to discarded blood samples as previously described^[@CR10]--[@CR12]^. In brief, case and control medical record numbers are submitted to the Partners HealthCare Crimson system, which acts as an "honest broker" to match deidentified phenotypic data to discarded blood samples under an approved Institutional Review Board (IRB) protocol. Genotyping was performed in five batches that included case and control samples at the Broad Institute of MIT and Harvard using the Illumina PsychChip, a genomewide array that includes \~250,000 common variants as a backbone for GWAS imputation, \~250,000 rare variants, and \~50,000 additional markers focusing on psychiatrically relevant loci.

Genotype quality control (QC) and imputation {#Sec5}
--------------------------------------------

A total of 3772 BD cases and 4141 controls with genomewide data were available for this analysis. The number of genotyped BD cases by algorithm and controls are listed in Table [1](#Tab1){ref-type="table"} and described in Supplementary Figure [1](#MOESM1){ref-type="media"}. We performed QC on each genotyping batch separately with the following steps: (1) we removed single nucleotide polymorphisms (SNPs) with genotype missing rate \>0.05 before sample-based QC; (2) we excluded samples with genotype missing rate \>0.02, absolute value of heterozygosity \>0.2, or failed sex checks; (3) after sample-based QC, we then removed SNPs with missing rate \>0.02, with differential missing rate between cases and controls \>0.02, or failed Hardy--Weinberg equilibrium test (*p*-value \<1.0 × 10^−6^ in controls and *p*-value \<1.0 × 10^−10^ in cases). To merge genotyping batches for imputation and analyses, we performed batch QC by removing SNPs with differential missing rate \>0.005 between batches or significant batch association (*p*-value \<5.0 × 10^−8^ between controls form different batches). All QC were conducted using PLINK v1.9^[@CR13]^.

The BD cases and controls included individuals from diverse populations. To control for population stratification and ensure the comparability between the current sample and previous European ancestry BD GWAS, we extracted samples with European ancestry for imputation and analyses. We used the International Haplotype Map project (HapMap3) samples as a population reference panel and performed principal component analysis (PCA) with the study samples and HapMap3 samples combined^[@CR14]^. We calculated the distance between each study sample and the average European population samples in HapMap3 using PC1 and PC2. We selected the study samples with distance to average European HapMap3 samples \<0.01 (Supplementary Figure [2](#MOESM1){ref-type="media"}--[4](#MOESM1){ref-type="media"})^[@CR14]^. We also removed one sample from each pair of related or duplicate samples ($\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$\hat \pi$$\end{document}$\> 0.2).

The final analytic dataset comprised 3330 BD cases (862 95-NLP, 1968 coded-strict, 2581 coded-broad, and 408 coded-broad-SV) and 3952 controls. The sum of the individual cases groups exceeds 3330 due to the non-hierarchical design in which cases were assigned to each phenotype for which they met inclusion criteria. We performed two-step genotype imputation with Eagle2 software for pre-phasing and IMPUTE2 on the European population study samples^[@CR15],[@CR16]^.

Statistical analysis {#Sec6}
--------------------

To assess whether our EHR-based phenotypes capture heritable components of BD, we used LD score regression (LDSC)^[@CR7],[@CR17],[@CR18]^ to estimate SNP-based heritability (*h*^2^~g~) for each EHR-based BD cohort. We then examined the degree to which heritable influences on our BD phenotypes overlap with those traditionally ascertained BD cases in other large-scale GWAS samples. To do this, we used LDSC to compute the genetic correlation (*r*~g~) between EHR-based BD samples and previously published BD GWAS by other ICCBD cohorts and the PGC (ICCBD + PGCBD)^[@CR7],[@CR17],[@CR18]^. The LDSC requires association summary statistics for genome-wide SNPs to estimate *h*^2^~g~ and *r*~g~. To obtain these summary statistics, we first performed GWAS for each of the four EHR-based BD definitions separately and for our combined BD case--control sample. We used a BD prevalence of 1% to obtain liability-scale *h*^2^~g~ from LDSC^[@CR19]--[@CR22]^. Prior studies have documented substantial genetic correlation between BD and other psychiatric disorder phenotypes, most notably schizophrenia (SCZ) and major depressive disorder (MDD)^[@CR20]^. To examine the genetic relationship between EHR-based BD samples and related phenotypes, we used LD Hub^[@CR23]^ to estimate *r*~g~ with schizophrenia (SCZ), major depressive disorder (MDD), subjective well-being, and, as a negative control, mean platelet volume (MPV). Finally, we performed genome-wide Cochran's *Q*-test to look for heterogeneity between association summary statistics from the EHR-based BD samples and the ICCBD + PGCBD samples at single variant level, using SNPs with association *p*-value \<0.001 in the ICCBD + PGCBD GWAS.

Results {#Sec7}
=======

We first estimated SNP-based heritability (*h*^2^~g~) for the four EHR-based BD samples (Table [1](#Tab1){ref-type="table"}). The liability-scale *h*^2^~g~ estimates were largest for the 95-NLP BD algorithm (0.24, *p* = 0.015) and smallest for the coded-broad-SV algorithm (0.0, *p* = 0.59), with intermediate but statistically significant values for the coded-strict and coded-broad algorithms. The *h*^2^~g~ of BD in the ICCBD + PGCBD sample was 0.23, which matches the *h*^2^~g~ for the 95-NLP algorithm but is greater than that of the rule-based algorithms. Of note, the coded-broad-SV case set had the least power with only 408 cases. As shown in Table [1](#Tab1){ref-type="table"}, this distribution of heritability estimates mirrors the relative PPVs obtained in our clinical validation study. To maximize the BD case--control sample size, we combined the BD case--control samples across algorithms into a single case--control dataset. Since the coded-broad-SV had no evidence of heritability, we created two combined BD datasets; one included all BD cases and one included all but the coded-broad-SV cases). The *h*^2^~g~ was 0.11 (*p*-value = 0.006) for all algorithms combined BD and 0.12 (*p*-value = 0.004) for all algorithms excluding coded-broad-SV.

We next estimated the SNP-based genetic correlation (*r*~g~) between the EHR-based BD samples and the ICCBD + PGCBD samples (Table [2](#Tab2){ref-type="table"}). The *r*~g~ estimates were 95-NLP (0.66), coded-strict (1.0), and coded-broad (0.74) were all statistically significant. (Note that *r*~g~ could not be estimated for coded-broad-SV given its *h*^2^~g~ of 0). The *r*~g~ for all algorithms excluding coded-broad-SV was 0.83 (*p* = 7.19 × 10^−7^). Adding coded-broad-SV BD cases to the combined case set did not substantially change the *r*~g~ estimate although the standard error (SE) increased and *p*-value rose to 2.88 × 10^-6^. We also estimated the pairwise *r*~g~ between the EHR-based BD case--control samples and the final combined BD samples. As expected, the *r*~g~ estimates are high and ranged from 0.90 to 0.98 between algorithms, and were 1.00 between each algorithm and the combined sample (excluding coded-broad-SV). Finally, the *r*~g~ between ICCBD and PGCBD was 1.00 (SE = 0.065, *p*-value = 1.45 × 10^-74^).Table 2SNP-based genetic correlation (*r*~g~) between EHR-based bipolar disorder and bipolar disorder ascertained by traditional methods from ICCBD + PGCBD*r*~g~ (SE)*p*-value^a^95-NLP0.66 (0.16)3.69 × 10^−5^Coded-strict1.00 (0.29)2.40 × 10^−4^Coded-broad0.74 (0.15)8.11 × 10^−7^All except coded-broad-SV0.83 (0.17)7.19 × 10^−7^Genetic correlation was not estimated for coded-broad-SV due to SNP-based heritability estimate of 0*SE* standard error^a^Test for different from 0

Given prior evidence that traditionally ascertained BD GWAS show significant positive genetic correlations with SCZ and MDD^[@CR18],[@CR20]^ and significant negative genetic correlation with subjective well-being^[@CR24]^, we examined these correlations using our EHR-based algorithms as another index of their genetic validity. As a negative control, we also examined their genetic correlation with mean platelet volume (MPV), a phenotype for which we would not expect significant genetic correlation. (Fig. [1](#Fig1){ref-type="fig"}; Supplementary Table [1](#MOESM1){ref-type="media"}). For comparison, we also examined these patterns of correlation with BD in traditionally ascertained samples (ICCBD + PGCBD). As expected based on prior data^[@CR18],[@CR20],[@CR24]^, EHR-based BD was positively genetically correlated with SCZ and MDD, negatively correlated with subjective well-being, and uncorrelated with MPV (Fig. [1](#Fig1){ref-type="fig"}). Of note, the BD-MDD genetic correlation was higher than the BD-SCZ genetic correlation using EHR-based BD (left side, Fig. [1](#Fig1){ref-type="fig"}) while the opposite was true using the ICCBD + PGCBD cohort (right side, Fig. [1](#Fig1){ref-type="fig"}). We hypothesized that this difference in *r*~g~ patterns might be related to differences in the proportions of BD subtypes among the EHR-based BD cases and those included in the traditionally ascertained BD samples. To investigate this, we calculated the percentage of BD case subtypes, including bipolar I disorder (BD1), bipolar II disorder (BD2), schizoaffective disorder bipolar type (SAB), and bipolar disorder not otherwise specified (NOS) for the EHR-based BD cases and the ICCBD cases (the subtypes of PGCBD cases were not available). We found that the EHR-based BD cases comprised a lower proportion of SAB subtype cases (0.6--1.6%) compared with the ICCBD samples (9.1%) (Supplementary Figure [5](#MOESM1){ref-type="media"}). This difference would be consistent with a relatively smaller BD-SCZ genetic correlation seen in the EHR-based samples compared with the ICCBD samples.Fig. 1SNP-based genetic correlation (with 95% confidence interval) between bipolar disorder based on different ascertainment methods and other traits

Finally, we performed Cochran's *Q*-test to identify potential heterogeneity of the association summary statistics between EHR-based BD samples and the ICCBD + PGCBD samples. This analysis was restricted to SNPs with association *p* \< 0.001 in the ICCBD + PGCBD GWAS in order to exclude SNPs with weak association results whose directionality might be less robust. We identified a single locus with significant heterogeneity across the genome after Bonferroni correction (SNP *N* = 28,320) for both coded-broad and for the combined EHR-BD sample (excluding coded-broad-SV) (Fig. [2](#Fig2){ref-type="fig"}). This locus on chromosome 22 (peak *Q*-test *p*-value at rs196065 = 3.34 × 10^−7^), showed modest association with BD (*p*-value = 5.78 × 10^−5^ in ICCBD + PGCBD) and did not overlap with any previously reported BD-associated loci. Thus, we found negligible evidence of heterogeneity of genomewide association results between EHR-based BD and traditionally ascertained BD.Fig. 2Genome-wide Cochran's *Q*-test for heterogeneity of SNP effects between ICCBD + PGCBD and EHR-based bipolar disorder.Red line shows the Bonferroni-corrected significance level for the *Q*-test. SNPs are selected with association *p*-value threshold of 0.001 based on ICCBD + PGCBD analysis (total number of SNPs = 28,320)

Discussion {#Sec8}
==========

As an ever-growing longitudinal repository of the clinical phenome, EHRs represent a new and powerful resource for psychiatric research^[@CR9]^. Nevertheless, their utility depends on the validity of the clinical and phenotypic data that can be extracted. We have previously demonstrated the feasibility of deriving diagnoses with high predictive value compared with a gold standard of clinician-administered diagnostic interviews^[@CR10]^. However, in the context of psychiatric genetic research, establishing the genetic validity of these phenotypes is crucial. In the present study, using genomewide genotype data for more than 7000 cases and controls, we demonstrate that EHR-based algorithms can be used to ascertain BD phenotypes that are heritable and genetically comparable to traditionally ascertained samples. Automated algorithm-based phenotyping linked to biospecimens provides substantial efficiencies in terms of the time and costs involved in assembling large-scale samples for genetic research. Prior simulations have documented up to a ten-fold reduction in the cost associated with phenotyping and sample collection^[@CR11]^. Using our case/control BD definitions linked to discarded blood samples, we were able to collect approximately 5000 controls over 10 weeks and more than 4000 cases over 3 years. As described below, three sets of findings from our analyses are particularly noteworthy.

First, our results document that EHR-based diagnostic algorithms can be used to ascertain BD phenotypes that yield SNP-based heritability comparable to that observed in GWAS that have relied on more time-intensive, cost-intensive, and labor-intensive recruitment and diagnostic evaluation. The highest heritability (0.24) was seen with our 95-NLP algorithm which combined NLP of narrative test features and coded EHR data. This estimated heritability was nearly identical to that derived from GWAS of the larger traditionally ascertained cohorts of the international ICCBD and PGC (*h*^2^~g~ = 0.23 for 13,902 cases and 19,279 controls). The 95-NLP algorithm also achieved the highest positive predictive value in our previous clinical validation study. For two of the remaining three algorithms which involved rule-based algorithms of structured EHR data, we also observed significant, though relatively lower, heritability estimates (*h*^2^~g~ = 0.09--0.12). The least restrictive algorithm (coded-broad-SV) did not exhibit significant heritability, though the small sample size of this subgroup limited the power of our analyses. Of note, this last algorithm also performed poorly in our prior clinical validation study (PPV = 0.5). Nevertheless, the overall heritability of our EHR-based BD was 0.12 (*p* = 0.004), dropping slightly to 0.11 (*p* = 0.006) when the coded-broad-SV was included. In addition, the EHR-based BD definitions were nearly perfectly genetically correlated. Pairwise genetic correlations between the phenotypes ranged from 0.98 to 1.0 except for 95-NLP and coded-broad-SV (*r*~g~ = 0.90).

Second, we found that our cohorts ascertained by automated EHR phenotyping exhibited substantial genetic correlations (*r*~g~) with the large ICCBD + PGCBD samples. Overall, the *r*~g~ between our EHR-based BD case/control samples and the ICCBD + PGCBD samples was 0.83 (*p* = 2.88 × 10^−6^), demonstrating that our approach captures genetic influences that strongly overlap with those acting on BD in traditionally ascertained samples. In addition to providing further genetic validation of EHR-derived phenotypes, these results indicate that such samples can be combined with other existing samples to enhance the power of genetic discovery.

Finally, we demonstrate that our phenotyping approach replicates patterns of cross-disorder genetic overlap that have previously been reported in genetic studies of BD^[@CR7],[@CR25]^. In particular, EHR-based BD exhibited positive genetic correlations with SCZ and MDD and negative correlations with subjective well-being. Once again, this supports the genetic validity of our algorithm-defined BD phenotype. Unexpectedly, the genetic correlation with SCZ was less than that seen with MDD, a finding that may be attributable to the relatively low frequency of SAB cases in our sample.

We acknowledge that our results have certain limitations. First, our sample size, while substantial, is smaller than that of some other existing samples (e.g., ICCBD and PGCBD), which may have limited the power and precision of our heritability and genetic correlation analyses. Second, the portability of our specific phenotyping algorithms to other healthcare settings remains to be determined. Notably, however, our results demonstrate that a range of algorithms---with and without NLP and using diagnostic rules of varying stringency---yield phenotypes that are clinically and genetically comparable to those obtained by in-person standardized diagnostic assessments. With the exception of the 95-NLP algorithm, each of our case and control phenotypes are based on structured diagnostic codes and medication data that are widely available and standardized in EHR systems, facilitating their application in other systems. In the case of the 95-NLP algorithm, the narrative features comprise nine features (enumerated in Castro et al.^[@CR10]^) that refer to either a diagnosis, medication, or visit type---none of which we would expect to be unique to our healthcare system. There is now a growing literature demonstrating the portability of EHR-based diagnostic algorithms^[@CR26]^. In particular, the Electronic Medical Records and Genomics (eMERGE) Network has created a catalog of EHR-based diagnostic phenotypes (PheKB) that includes NLP-based algorithms developed in one healthcare system and applied in others^[@CR27]^. Finally, diagnostic misclassification could bias or reduce the power of genetic analyses^[@CR28],[@CR29]^. However, this caveat applies to any phenotyping method, and we note that our clinical validation studies^[@CR10]^ demonstrate relatively low levels of diagnostic misclassification in comparison to a gold-standard clinician-administered diagnostic interview.

In summary, the current study provides the first genetic validation of EHR-based phenotyping for BD and suggests that automated phenotyping algorithms can identify samples that are highly genetically correlated with those ascertained through conventional methods. Taken together, the present results and those of our prior clinical validation study, suggest that the use of any or all three of the heritable EHR-based algorithms we derived (i.e., 95-NLP, coded-strict, and coded-broad) can facilitate genetic studies of bipolar disorder. High throughput phenotyping using the large data resources available in the EHR database represents a viable method for accelerating psychiatric genetic research.
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